Clinical Trial Recruitment by Text: Rules & Workflows

Clinical trial recruitment fails quietly and often: studies close late or underpowered not because eligible participants do not exist, but because the recruitment funnel leaks at every step between "saw a flyer" and "signed the consent." Text messaging attacks the leaks directly. It reaches candidates on the channel they answer, screens interest in minutes instead of phone-tag weeks, and then carries the retention load, visit reminders, check-ins, and rescheduling, for the length of the study. What makes research texting distinctive is its oversight regime: recruitment materials are part of the research and answer to an institutional review board (IRB), and federal human-subjects rules shape what messages may say and do. This guide covers the rules and the workflows. It is general information, not legal advice.

Key takeaways:

• Recruitment communications are considered part of the informed consent process's beginning; FDA guidance treats advertising and recruitment materials as subject to IRB review.
• The federal frameworks are FDA regulations at 21 CFR Part 50 (informed consent) and 21 CFR Part 56 (IRBs), plus the Common Rule at 45 CFR Part 46 for federally supported research.
• Texting can invite, screen, schedule, and remind; it cannot replace informed consent, which remains a documented process under 21 CFR 50.
• HIPAA governs recruitment from clinical populations: identifying candidates from records and contacting them runs through defined pathways, and messaging platforms need a signed business associate agreement (BAA).
• Retention is where texting compounds: visit reminders and easy rescheduling protect the enrollment a site worked hard to win.

The oversight frame: why recruitment texts see an IRB first

Human-subjects research in the United States runs under two overlapping regimes. FDA-regulated studies follow 21 CFR Part 50 (protection of human subjects, including informed consent requirements) and 21 CFR Part 56 (IRB review). Federally supported research follows the Common Rule at 45 CFR Part 46. Both put an IRB between researchers and participants, and FDA guidance has long stated that advertising and recruitment materials are an extension of the recruitment process and should be reviewed by the IRB before use.

For a texting program, that means:

• Message templates are study documents. Invitation texts, screening scripts, reminder language, and the automated answers a system may give all go to the IRB as recruitment materials.
• Claims discipline is mandatory. Recruitment language may not overstate benefit, promise results, or emphasize payment in ways that unduly influence. Neutral, factual invitation language is the standard.
• Changes get re-reviewed. A revised template is an amendment, not a quick edit.

This is a natural fit for platform-based messaging, where templates are versioned, approvals are logged, and free-lancing is structurally impossible, an auditability posture that also serves the sponsor's monitoring obligations.

Finding candidates: the HIPAA pathways

Recruiting from a clinical population means using protected health information (PHI) to identify and contact people, and HIPAA provides specific routes:

1. Authorization. Patients may sign a HIPAA authorization permitting research contact, often gathered in advance through research registries and "contact me about studies" programs.
2. IRB-approved waivers. An IRB or privacy board may waive authorization for recruitment contact under the criteria at 45 CFR 164.512(i), typically allowing the care team or honest brokers to identify eligible patients.
3. Preparatory to research. Researchers may review records to prepare a study, though contacting patients generally requires one of the above.
4. Treatment-context invitations. A patient's own provider may discuss a study during care.

Whichever path applies, the messaging layer must be governed: a platform storing recruitment conversations is a business associate under 45 CFR 160.103 and needs a signed BAA per 45 CFR 164.502(e), with encryption in transit (TLS 1.3) and at rest (256-bit AES) and audit logging. The Telephone Consumer Protection Act (TCPA) sits alongside: prior express consent for automated texts, documented at registry signup or intake, with STOP honored instantly. The consent-capture mechanics are the same ones described in our guide to collecting and documenting texting consent.

The recruitment funnel, rebuilt on texting

Invitation. An IRB-approved text introduces the study neutrally and offers a low-commitment next step:

Lakeside Research Center: We are enrolling adults with type 2 diabetes in a research study of an investigational medication. Participation is voluntary and includes study-related care at no cost. Reply INFO to learn more or STOP to opt out.

Pre-screening. Interested candidates answer a short, IRB-approved question flow in the thread, age range, diagnosis confirmation, key exclusions, in minutes rather than telephone rounds. An AI Powered Helper can conduct this structured flow from approved scripts, answer logistics questions (location, time commitment, compensation as approved), and route every clinical or protocol question to study staff. It screens against criteria; it never gives medical advice or characterizes the investigational product.

Scheduling the consent visit. Qualified candidates book the screening visit in-thread from real calendar slots. Speed matters enormously here: interest decays daily, and the funnel's worst leak is the gap between "I qualify" and "I have an appointment."

Informed consent, properly separate. Consent itself is the regulated conversation under 21 CFR 50.20 and following: the elements of consent, the opportunity to ask questions, and documentation per 21 CFR 50.27. Texting delivers the appointment, the reminder, and the consent document for advance reading where the IRB approves; it does not replace the consent discussion.

Retention: the half of recruitment nobody budgets for

A participant lost mid-study can cost more than one never enrolled, in data quality and in the enrollment that must replace them. The retention workload is almost perfectly text-shaped:

• Visit reminders on the proven multi-touch cadence, with confirm and reschedule replies handled in-thread.
• Windowed-visit management. Protocol visits with allowable windows get escalating reminders as the window narrows, protecting protocol compliance.
• Dosing and diary prompts where the protocol and IRB approve them, timestamped and logged.
• Check-ins between visits that keep the study present and surface problems early; concerning replies escalate to coordinators immediately.
• Practical logistics: parking, fasting instructions, stipend timing, what to bring, answered instantly from approved content.

Every message and reply is logged against the participant record, which serves the site's documentation obligations and gives coordinators a live view of engagement instead of a surprise no-show. These are the same mechanics that power patient engagement platforms in clinical care, pointed at protocol adherence. FRANSiS supports research sites and networks with this full loop, HIPAA compliance supported, a signed BAA included, and template governance that fits IRB workflows.

Frequently asked questions

Is it legal to recruit clinical trial participants by text message?

Yes, within the oversight structure: recruitment materials, including text templates, should be IRB-reviewed per FDA guidance; contacting candidates from clinical records follows HIPAA pathways such as authorization or an IRB-approved waiver; and the TCPA requires prior express consent for automated texts, with STOP honored immediately.

Do recruitment text messages need IRB approval?

Yes. FDA guidance treats advertising and recruitment materials as part of the recruitment process subject to IRB review, and that extends to invitation texts, screening scripts, and automated reply content. Template changes are amendments that return to the IRB, which makes versioned platform templates a natural fit.

Can informed consent happen over text?

No. Texting can deliver study information, schedule the consent visit, and send documents for advance reading where approved, but informed consent under 21 CFR 50 is a documented process with required elements and the opportunity for discussion. Electronic consent systems exist, but they are distinct, validated processes, not SMS threads.

How does texting improve trial retention?

By carrying the between-visit workload: multi-touch visit reminders with in-thread rescheduling, window management for protocol visits, approved dosing or diary prompts, and logistics answers on demand. Engagement is logged continuously, so coordinators see disengagement early instead of discovering it at a missed visit.

What infrastructure does a research site need for compliant texting?

A platform with a signed BAA, encryption in transit and at rest, audit logs, consent tracking, template version control, and escalation routing to study staff. An AI Powered Helper adds screening-at-scale and instant logistics answers while keeping clinical and protocol questions with humans.

Conclusion

Trials do not fail to enroll because candidates are missing; they fail because the funnel between interest and signature is slow, and the calendar between visits is silent. Texting fixes the tempo at both ends, under exactly the oversight research deserves: IRB-approved words, HIPAA-governed plumbing, and consent conversations left where they belong, with humans. Sites that build this layer recruit faster and, just as importantly, keep the participants they earn.

Running studies and tired of leaky funnels? Contact the FRANSiS team to see IRB-friendly recruitment and retention texting with template governance, a signed BAA included, and an AI Powered Helper that screens and schedules while your coordinators coordinate.